Elutia (ELUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, David Colpman and Kevin Rakin, is up for shareholder vote.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is proposed.
Approval sought for the First Amendment to the Amended and Restated 2020 Incentive Award Plan.
Advisory vote on executive compensation ("say on pay") and on the frequency of future say-on-pay votes are included.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals presented.
Shareholders may withhold authority for individual nominees or vote for all.
Executive compensation and say-on-pay
Advisory, non-binding vote on executive compensation is included.
Shareholders to select preferred frequency (one, two, or three years) for future say-on-pay votes.
Latest events from Elutia
- FDA clearance for EluPro and improved margins offset by a $28.2M net loss and going concern risks.ELUT
Q2 20248 Jul 2026 - New drug-eluting biologic envelope gains traction with major partner and strong clinical benefits.ELUT
Planet MicroCap Showcase: VEGAS 20258 Jul 2026 - EluPro's rapid adoption and a robust pipeline position the company for significant growth.ELUT
Cantor Global Healthcare Conference 20258 Jul 2026 - Drug-eluting mesh targets high breast reconstruction infection rates, with launch expected next year.ELUT
Planet MicroCap Las Vegas 202617 Jun 2026 - Antibiotic-eluting matrix targets high breast reconstruction infection rates in a $1.5B market.ELUT
16th Annual LD Micro Invitational Conference18 May 2026 - Net sales up 6%, gross margin improved, and NXT-41/41x on track for 2026–2027 launch.ELUT
Q1 202617 May 2026 - Shareholders will vote on director elections, auditor ratification, and key compensation matters.ELUT
Proxy filing23 Apr 2026 - Q4 revenue up 16%, BioEnvelope sale drove debt repayment, and NXT-41x FDA process advanced.ELUT
Q4 202511 Mar 2026 - EluPro launches as a biologic alternative in the cardiac device protection market, with full rollout in 2025.ELUT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026